NCT00938730View on ClinicalTrials.gov

A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation

PHASE2CompletedINTERVENTIONAL
Enrollment

1,280

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Atrial Fibrillation
Interventions
DRUG

YM150

oral

DRUG

Warfarin

oral

Trial Locations (170)

13

Prague

1091

BC Amsterdam

1100

Vienna

1160

Vienna

1202

Sofia

1307

Dresden

1309

Sofia

1407

Sofia

1500

Benoni

1505

Sofia

1606

Sofia

2000

Tábor

2625

AD Delft

3181

Victoria

3680

Kyiv

4021

Kippa-Ring

4050

Kyiv

4066

Auchenflower

4092

Chatsworth

4320

Umhlanga

4400

Tongaat

4510

Caboolture

4708

AE Roosendaal

5000

Iloilo City

5800

Pleven

6400

Dimitrovgrad

6850

Worcester

7130

Somerset West

7530

Bellville

10115

Berlin

10117

Berlin

10138

Tallinn

10330

Bangkok

10367

Berlin

10617

Tallinn

16100

Nazareth

18009

Cherkassy

20307

Narva

21005

Vinnytsia

22100

Nahariya

25630

Besenov

30008

Murcia

34121

Kassel

40113

Ústí nad Labem

41009

Seville

42202

Nashik

43024

Lutsk

46002

Ternopil

47500

Selangor Darul Ehsan

50200

Chiang Mai

50586

Kuala Lumpur

51014

Tartu

55116

Mainz

58099

Hagen

61002

Kharkiv

61018

Kharkiv

61037

Kharkiv

61039

Kharkiv

61178

Kharkiv

61231

Bad Nauheim

64283

Darmstadt

65059

Odesa

68169

Mannheim

69118

Zaporizhzhya

73601

Havirov-mesto

75015

Paris

76075

Ivano-Frankivsk

76100

Rehovot

79013

Lviv

83114

Donetsk

94501

Komárno

101990

Moscow

117485

Moscow

163045

Arkhangelsk

194156

Saint Petersburg

199106

Saint Petersburg

214018

Smolensk

300035

Tula

380054

Ahmedabad

410028

Saratov

411001

Pune

411004

Pune

440012

Nagpur

454021

Chelyabinsk

500036

Hyderabaad

524003

Nellore

560034

Bangalore

560052

Bangalore

560053

Bangalore

625026

Tyumen

625107

Madurai

630008

Novosibirsk

630012

Novosibirsk

630117

Novosibirsk

643063

Tomsk

644046

Omsk

700054

Kolkata

04416

Markkleeberg

H-8230

Balatonfüred

H-1134

Budapest

H-4030

Debrecen

H-9200

Mosonmagyaróvár

H-4400

Nyíregyháza

H-8000

Székesfehérvár

078-8214

Asahikawa

243-8550

Atsugi

113-8603

Bunkyō City

574-0074

Daitō

251-8550

Fujisawa

274-8503

Funabashi

193-0098

Hachiōji

311 3193

Higashiibaraki-gun

Unknown

Hiroshima

920 8650

Kanazawa

714-0043

Kasaoka

596-8522

Kishiwada

364-8501

Kitamoto

204 8585

Kiyose

651-1145

Kobe

153-8515

Meguro-ku

020-8505

Morioka

783-8509

Nankoku

060-0011

Sapporo

063 0005

Sapporo

983 8520

Sendai

901-0496

Shimajiri-gun

162-8543

Shinjyuku-ku

421-0117

Shizuoka

939-8511

Toyama

351 0102

Wako

227-0046

Yokohama

41-902

Bytom

81-423

Gdynia

81-472

Gdynia

40-635

Katowice

25-735

Kielce

30-082

Krakow

91-425

Lodz

20-954

Lublin

87-100

Torun

00-909

Warsaw

02-057

Warsaw

02-097

Warsaw

50-981

Wroclaw

08501

Bardejov

02601

Dolný Kubín

04022

Košice

03301

Liptovský Hrádok

03601

Martin

0157

Centurion

0044

Moreletapark

603-175

Busan

501-757

Gwangju

405-760

Incheon

120-752

Seoul

137-701

Seoul

138-736

Seoul

158-710

Seoul

08840

Viladecans

02038

Kyiv

02660

Kyiv

03680

Kyiv

KT 15 2BH

Addlestone

BA2 3HT

Bath

B18 7QH

Birmingham

DD1 9SY

Dundee

KT24 6QT

East Horsley

SE5 8AF

London

CB7 5JD

Soham

SO16 6YD

Southampton

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT00938730 - A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation | Biotech Hunter | Biotech Hunter